TIL and NK Cell Therapy CMC — Complexity at the Least-Standardized CMC Frontier

Tumor-infiltrating lymphocyte and NK cell therapies occupy the frontier of cell therapy CMC. The regulatory expectations are evolving — but CBER’s fundamental requirements for potency, identity, and manufacturing consistency are not.

TIL and NK cell programs are advancing through clinical development with increasing momentum, yet their CMC packages remain among the least standardized in the cell therapy space. For regulatory affairs and CMC teams, this creates a structural challenge: CBER’s Office of Therapeutic Products (OTP, formerly the Office of Tissues and Advanced Therapies) has well-established expectations inherited from the CAR-T development history, but TIL and NK cell products carry distinct manufacturing architectures, biological complexity, and functional readout requirements that do not map cleanly onto prior approval precedent. The cost of misreading that landscape is not a single deficiency letter — it is a clinical hold, a delayed BLA, or a product that reaches the review division without the potency data that can support licensure.

TIL Therapy Manufacturing: The Patient Biopsy, Expansion Process, and the CMC Complexity

TIL therapy begins with a surgical biopsy — a starting material that is neither standardized nor scalable in the way a leukapheresis unit is for CAR-T manufacturing. The patient’s tumor digest produces an initial TIL population whose composition varies with tumor histology, immune infiltration grade, prior treatment history, and biopsy handling time. From that variability, the manufacturing process must produce a product that is consistent enough in identity, purity, and function to justify a defined lot release specification — and that tension between biological variability and regulatory consistency is the defining CMC challenge for TIL programs. FDA’s Guidance for Industry: Considerations for the Design of Early-Phase Clinical Trials of Cellular and Gene Therapy Products (finalized June 2015) makes clear that even for novel immune effector cell products, the sponsor must demonstrate control over the manufacturing process sufficient to ensure consistent product quality — a principle that FDA’s companion Potency Tests for Cellular and Gene Therapy Products guidance (2011, discussed below) extends specifically to require that potency testing reflect the mechanism of biological activity, not merely phenotypic composition.

The rapid expansion protocol, or REP, is the most consequential manufacturing step in TIL production and the most frequently under-characterized in CMC packages reviewed at the IND stage. The REP — typically a 10- to 14-day expansion phase using high-dose IL-2 and anti-CD3 stimulation in the presence of irradiated allogeneic feeder cells — can expand TIL populations 1,000-fold or more, but it also reshapes the CD4:CD8 ratio, the proportion of antigen-experienced effectors, and the exhaustion phenotype of the final product in ways that are highly sensitive to feeder cell source, irradiation dose, and IL-2 concentration. CBER expects REP conditions to be defined as critical process parameters with demonstrated acceptable ranges, supported by process characterization data — not merely described as a historical process with undefined operating bounds. Sponsors who present REP conditions as fixed nominal values without CPP justification consistently receive information requests asking for the bracketing studies that should have been part of the process development package.

The use of allogeneic feeder cells in the REP introduces a regulatory risk that is often underweighted in early CMC planning. Irradiated peripheral blood mononuclear cells from pooled donors represent a biological starting material with its own identity, sterility, and adventitious agent testing requirements. CBER has issued clear expectations through its cell therapy-specific CMC guidance and public communications (and, for feeder-cell-dependent products that also involve genetic modification, through its CMC Information for Human Gene Therapy INDs (2020)) that feeder cell lots used in clinical manufacturing must be characterized, tested, and documented in the CMC package — and that if feeder cells are used without a formal risk assessment and regulatory notification, the deficiency will be identified during IND review. Equally important, the final drug product must include residual feeder cell testing to confirm clearance, with a specified acceptance criterion in the lot release specification.

NK Cell Therapy: Allogeneic Sources, Manufacturing Architecture, and the CQA Framework

NK cell therapy programs operate across a wider source diversity than any other cell therapy platform currently in clinical development. Peripheral blood-derived NK cells, umbilical cord blood NK cells, iPSC-derived NK cells, and NK cell lines each present distinct manufacturing starting materials with different identity markers, expansion kinetics, and functional profiles. The CMC consequence of that diversity is that there is no universal CQA framework for NK cell products — each platform requires a product-specific critical quality attribute definition strategy rooted in the mechanism of action, the clinical dose, and the analytical methods available to measure those attributes at lot release. EMA/CAT guidance on NK cell products and CBER presentations at ASGCT and FACT meetings have both emphasized that identity testing for NK cells must include at minimum CD56 and CD3 co-staining — to confirm NK cell enrichment and T cell depletion, respectively — and that the absence of T cell identity testing in a nominally NK cell product will generate a major deficiency.

For allogeneic NK cell programs, the manufacturing architecture introduces CMC considerations that parallel allogeneic CAR-T in their regulatory treatment: donor qualification, lot-to-lot variability, extended characterization requirements, and comparability across manufacturing scale changes. Unlike autologous TIL, where each lot is patient-specific and comparability is assessed through process consistency rather than product-to-product comparison, allogeneic NK cell programs must demonstrate that lots manufactured from different donors or at different scales are comparable — a requirement that draws directly on ICH Q5E comparability principles and demands a pre-defined comparability protocol with acceptance criteria specified before the bridging manufacturing run. Sponsors who initiate scale changes between Phase 1 and Phase 2 without a prospective comparability protocol in place routinely face FDA requests for retrospective justification that is far more difficult to provide than the prospective study would have been.

Cryopreservation strategy is a critical CMC element for both TIL and NK cell products that is frequently underspecified at the IND stage. The standard approach for T cell and NK cell products uses 10% v/v DMSO as the primary cryoprotectant — formulated in products such as CryoStor CS10 — which reduces intracellular ice crystal formation through DMSO’s penetrating cryoprotectant mechanism. For more sensitive NK cell populations, particularly iPSC-derived NK cells, CS5 (5% v/v DMSO) formulations are used to reduce DMSO-mediated toxicity while maintaining cryoprotection. The controlled-rate freezing protocol — typically −1°C/min from 4°C to −40°C, then −5°C/min to −90°C before transfer to liquid nitrogen vapor phase storage at −196°C — must be validated using a programmable controlled-rate freezing device, with thermocouple mapping of both the freezing bag and the unit, and full IQ/OQ/PQ documentation. Post-thaw viability acceptance criteria of ≥70% by trypan blue exclusion or 7-AAD flow cytometry are standard for T cell and NK cell lots, and this threshold must appear as a defined specification in the lot release document — not as a historical observation.

Potency Assays for TIL and NK Cell Therapies: The Function-Based Methods CBER Requires

FDA’s 2011 guidance on Potency Tests for Cellular and Gene Therapy Products establishes that potency testing must measure a biological activity that is relevant to the product’s intended mechanism of action — and that phenotypic markers alone do not satisfy the potency requirement unless a clear mechanistic linkage between marker expression and biological function has been established and accepted by CBER. For TIL programs, this means that a lot release specification built entirely around CD8+ percentage, total viable cell count, and sterility does not contain a potency assay as CBER defines the term. The required element is a cytolytic or cytokine-release functional assay — such as a co-culture cytotoxicity assay against a relevant target cell line or autologous tumor digest, or an IFN-γ ELISPOT following antigen stimulation — that demonstrates the lot’s capacity to perform the biological activity attributed to TIL in the clinical setting.

For NK cell therapy programs, the potency assay design challenge centers on the effector-to-target ratio used in the cytotoxicity assay. NK cell cytotoxicity assays — typically chromium-51 release, calcein-AM fluorescence, or luciferase-based killing assays — are highly sensitive to E:T ratio, and a ratio that is too high will produce 100% killing for virtually any NK cell lot, eliminating the discriminatory power needed to distinguish clinical-grade material from subpotent lots. CBER presentations at ASGCT and FACT meetings have highlighted this as a recurring deficiency: programs that set their E:T ratio at 10:1 or higher against highly susceptible target lines such as K562 routinely produce assay readouts that cannot detect manufacturing process failures. The appropriate E:T ratio must be established during assay development through a range-finding study that identifies the ratio at which the assay discriminates between lots with different functional profiles, and that ratio — along with the target cell line, the assay duration, and the acceptance criterion — must be fixed in the lot release specification and validated before Phase 2 enrollment.

The convergence of TIL and NK cell potency assay challenges points to a single regulatory conclusion: CBER expects sponsors to have made deliberate, documented decisions about what biological activity the assay measures, why that activity is relevant to the clinical mechanism, and how the acceptance criterion was derived. ICH Q6B’s principles for biological product specifications — applied through CBER’s cell therapy-specific expectations — require that specifications be based on manufacturing data from the development history, not set arbitrarily. A potency assay with an acceptance criterion that was never bracketed against clinical lots from the development program, or that was set at a level no manufactured lot has ever failed, does not satisfy this requirement and will be identified as such in CBER review.

Building TIL and NK Cell Therapy CMC Programs in a Space Without Established Regulatory Precedent

The XGene TIL/NK Cell CMC Characterization and Release Framework is a tailored CMC design methodology developed specifically for TIL and NK cell therapy programs navigating CBER and EMA review in the absence of established product-class precedent.

Step 1 — Manufacturing Process Characterization Mapping: Systematically identify every process step — from biopsy receipt or donor leukapheresis through REP or expansion, harvest, formulation, cryopreservation, and release — and classify each input parameter as critical, key, or non-critical based on impact on product CQAs, using process characterization data to support the classification rather than engineering judgment alone. This step produces the process parameter table that CBER expects in Module 3.2.S.2.2 and which anchors the entire manufacturing control strategy.

Step 2 — Product-Specific CQA and Potency Assay Strategy Definition: For each product CQA, define the analytical method, the basis for the acceptance criterion, the assay qualification status (fit-for-purpose vs. validated), and the linkage to clinical mechanism of action — with explicit documentation of why phenotypic markers alone are insufficient and what functional assay has been selected to satisfy the FDA Potency Tests for Cellular and Gene Therapy Products (2011) requirement. This step produces the potency assay strategy document that becomes the backbone of the lot release specification.

Step 3 — Feeder Cell Risk Assessment and Residual Testing Protocol: For programs using irradiated allogeneic feeder cells in expansion or REP, develop a formal feeder cell risk assessment addressing donor qualification, adventitious agent testing, lot release criteria, and clearance strategy — including the residual feeder cell testing method (typically a species-specific or HLA-based flow cytometric assay) and its acceptance criterion in the final drug product specification. This step produces the documentation CBER expects and prevents the most commonly cited major deficiency in TIL IND CMC packages.

Step 4 — Cryopreservation and Cold Chain Validation Package: Design and execute the cryopreservation validation program — including controlled-rate freezer mapping (temperature uniformity ≤2°C across all positions), freeze-thaw cycle qualification, container closure integrity testing by vacuum decay or dye ingress after cycling, and shipping validation with worst-case time and temperature excursions — producing the cold chain validation summary that supports Module 3.2.P.3 and satisfies CBER’s expectation for a documented shipping validation study with GPS temperature logging.

The output of the XGene TIL/NK Cell CMC Characterization and Release Framework is a submission-ready CMC package — with each regulatory expectation mapped to a specific document, record, or assay result in the eCTD — that a program can take directly into IND submission or pre-BLA meeting preparation without rebuilding the evidence base from scratch.

TIL and NK cell therapy programs that reach Phase 2 or Phase 3 without a function-based potency assay, a defined CPP matrix for the expansion process, and a validated cold chain package are not facing a documentation gap — they are facing a manufacturing control gap that will require prospective remediation studies at the worst possible point in the development timeline. The cost of that remediation is not only measured in time and resources; it is measured in the credibility of the CMC package at the BLA stage, where every retrospective justification carries a heavier evidentiary burden than a prospective study would have required. The least-standardized space in cell therapy is not a regulatory exemption — it is an environment in which the absence of precedent places a higher, not lower, burden on the sponsor to demonstrate control. Programs that invest in a rigorous CMC architecture early — one grounded in CBER’s stated expectations and executed with the analytical discipline those expectations demand — are the ones that reach the review division with a defensible package rather than a correctable one.

For your TIL or NK cell therapy product, can you identify today whether your potency assay measures antigen-specific or cytolytic biological activity (not just phenotype), the E:T ratio and target cell line used, the current acceptance criterion in the lot release specification, and whether residual feeder cell testing (if applicable) is performed and specified?